• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

长段股腘动脉闭塞的治疗:4F兼容自膨式镍钛合金支架的初步经验及文献综述

Treatment for long-segment femoro-popliteal obstructions: initial experience with a 4-F compatible self-expanding nitinol stent and review of the literature.

作者信息

Baumann F, Do D-D, Willenberg T, Baumgartner I, Diehm N

机构信息

Department of Clinical and Interventional Angiology, Swiss Cardiovascular Center, Inselspital, University Hospital of Bern, Bern, Switzerland.

出版信息

J Cardiovasc Surg (Torino). 2012 Aug;53(4):475-80.

PMID:22854527
Abstract

AIM

The aim of this paper was to evaluate the efficacy of a novel 4-F compatible self-expanding Nitinol stent for the treatment of long femoro-popliteal obstructions.

METHODS

This retrospective analysis includes patients with femoro-popliteal obstructions ≥ 120 mm in length, treated with a novel Nitinol stent (Pulsar-18) between February 2010 and December 2011. Patients were categorized as either intermittent claudication (IC) or critical limb ischemia (CLI). Primary endpoint was primary patency, secondary endpoints were target lesion revascularization (TLR).

RESULTS

A total of 31 patients (IC: N=18 and CLI: N=13) were included in the present series. Mean age was 73.3 ± 10.1 years and 71% (22/31) of the patients were male. Primary intervention was performed in 77.4% (24/31) of the patients and re-do revascularization in the remaining. Mean lesion length of femoro-popliteal obstructions was 163.5 ± 32.5 mm. Technical success was obtained in all patients. Mean follow-up duration was 316 ± 198 days. Primary patency rates were 83.3% in IC and 80.0% in CLI patients at 6 months and 64.1% and 54.9% at 12 months, respectively (P=0.84). Target lesion revascularization occurred in 5.6% of IC and 20.0% of CLI patients at 6 months and in 14.1% and 36.0% at 12 months, respectively (P=0.43).

CONCLUSION

Endovascular stenting of long femoro-popliteal lesions using the Pulsar-18 stent provides acceptable results with patency and restenosis rates comparable with data from literature for stenting of long femoro-popliteal obstructions.

摘要

目的

本文旨在评估一种新型4-F兼容自膨式镍钛诺支架治疗长段股腘动脉闭塞的疗效。

方法

本回顾性分析纳入了2010年2月至2011年12月间使用新型镍钛诺支架(Pulsar-18)治疗的股腘动脉闭塞长度≥120mm的患者。患者分为间歇性跛行(IC)或严重肢体缺血(CLI)。主要终点是原发通畅率,次要终点是靶病变血管重建(TLR)。

结果

本系列共纳入31例患者(IC:n = 18,CLI:n = 13)。平均年龄为73.3±10.1岁,71%(22/31)的患者为男性。77.4%(24/31)的患者进行了初次干预,其余患者进行了再次血管重建。股腘动脉闭塞的平均病变长度为163.5±32.5mm。所有患者均获得技术成功。平均随访时间为316±198天。IC患者6个月时的原发通畅率为83.3%,CLI患者为80.0%;12个月时分别为64.1%和54.9%(P = 0.84)。IC患者6个月时靶病变血管重建发生率为5.6%,CLI患者为20.0%;12个月时分别为14.1%和36.0%(P = 0.43)。

结论

使用Pulsar-18支架对长段股腘动脉病变进行血管内支架置入术可获得可接受结果,其通畅率和再狭窄率与文献中长段股腘动脉闭塞支架置入术的数据相当。

相似文献

1
Treatment for long-segment femoro-popliteal obstructions: initial experience with a 4-F compatible self-expanding nitinol stent and review of the literature.长段股腘动脉闭塞的治疗:4F兼容自膨式镍钛合金支架的初步经验及文献综述
J Cardiovasc Surg (Torino). 2012 Aug;53(4):475-80.
2
Endovascular treatment of popliteal artery segments P1 and P2 in patients with critical limb ischemia: initial experience using a helical nitinol stent with increased radial force.使用具有增加径向力的螺旋镍钛诺支架治疗伴有严重肢体缺血的患者的 P1 和 P2 段腘动脉:初步经验
J Endovasc Ther. 2012 Jun;19(3):450-6. doi: 10.1583/11-3591MR.1.
3
PEACE I all-comers registry: patency evaluation after implantation of the 4-French Pulsar-18 self-expanding nitinol stent in femoropopliteal lesions.PEACE I 所有受试者注册研究:4 法国规格的 Pulsar-18 自膨式镍钛合金支架植入股腘动脉病变后的通畅性评估
J Endovasc Ther. 2014 Jun;21(3):373-80. doi: 10.1583/13-4637R.1.
4
Mid-term clinical outcome and predictors of vessel patency after femoropopliteal stenting with self-expandable nitinol stent.股腘动脉自膨式镍钛合金支架置入术后中期临床结果及血管通畅性的预测因素。
J Vasc Surg. 2010 Sep;52(3):608-15. doi: 10.1016/j.jvs.2010.03.050. Epub 2010 Jun 22.
5
Primary stenting of the superficial femoral and popliteal artery.股浅动脉和腘动脉的初次支架置入术。
J Vasc Surg. 2009 Sep;50(3):542-7. doi: 10.1016/j.jvs.2009.04.019. Epub 2009 Jun 21.
6
Nitinol stent implantation vs. balloon angioplasty for lesions in the superficial femoral and proximal popliteal arteries of patients with claudication: three-year follow-up from the RESILIENT randomized trial.镍钛诺支架植入术与球囊血管成形术治疗间歇性跛行患者股浅动脉和腘动脉近段病变:RESILIENT 随机试验 3 年随访结果。
J Endovasc Ther. 2012 Feb;19(1):1-9. doi: 10.1583/11-3627.1.
7
Superficial femoral artery TASC D Registry: twelve-month effectiveness analysis of the Pulsar-18 SE nitinol stent in patients with critical limb ischemia.股浅动脉TASC D注册研究:Pulsar-18 SE镍钛合金支架治疗严重肢体缺血患者的12个月疗效分析
J Cardiovasc Surg (Torino). 2013 Aug;54(4):433-9.
8
Five-year outcomes of self-expanding nitinol stent implantation for chronic total occlusion of the superficial femoral and proximal popliteal artery.经皮腔内血管成形术联合自膨式镍钛合金支架置入治疗股浅动脉及腘动脉近段慢性完全闭塞的 5 年随访结果
Catheter Cardiovasc Interv. 2013 Sep 1;82(3):E251-6. doi: 10.1002/ccd.24935. Epub 2013 Apr 25.
9
The United States StuDy for EvalUating EndovasculaR TreAtments of Lesions in the Superficial Femoral Artery and Proximal Popliteal By usIng the Protégé EverfLex NitInol STent SYstem II (DURABILITY II).美国评估使用 Protégé Everflex Nitinol STent System II(耐久性 II)治疗股浅动脉和腘动脉近端病变的研究。
J Vasc Surg. 2013 Jul;58(1):73-83.e1. doi: 10.1016/j.jvs.2012.12.066. Epub 2013 May 2.
10
Influence of stent fracture on the long-term patency in the femoro-popliteal artery: experience of 4 years.支架断裂对股腘动脉长期通畅率的影响:四年经验
JACC Cardiovasc Interv. 2009 Jul;2(7):665-71. doi: 10.1016/j.jcin.2009.04.014.

引用本文的文献

1
Femoro-Supragenicular Popliteal Bypass with a Bridging Stent Graft in a Diffusely Diseased Distal Target Popliteal Artery: Alternative to Below-Knee Popliteal Polytetrafluoroethylene Bypass.在弥漫性病变的腘动脉远端目标血管中采用桥接支架移植物进行股-膝上腘动脉搭桥术:膝下腘动脉聚四氟乙烯搭桥术的替代方案
Korean J Thorac Cardiovasc Surg. 2017 Oct;50(5):371-377. doi: 10.5090/kjtcs.2017.50.5.371. Epub 2017 Oct 5.